Charles J N Lacey

Summary

Affiliation: Hull York Medical School
Country: UK

Publications

  1. ncbi Therapy for genital human papillomavirus-related disease
    Charles J N Lacey
    Hull York Medical School, University of York, Heslington, York YO10 5DD, UK
    J Clin Virol 32:S82-90. 2005
  2. ncbi Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study
    Charles J N Lacey
    Hull York Medical School, University of York, Heslington, York, UK
    AIDS 20:1027-30. 2006
  3. ncbi Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease
    Charles J N Lacey
    Hull York Medical School, University of York, Heslington, York, UK
    Vaccine 24:S3/35-41. 2006
  4. ncbi Unacceptable side-effects associated with a hyperosmolar vaginal microbicide in a phase 1 trial
    C J Lacey
    Centre for Immunology and Infection, Hull York Medical School, University of York, York, UK
    Int J STD AIDS 21:714-7. 2010
  5. ncbi Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom
    Sarah C Woodhall
    Hull York Medical School, University of York, Department of GU Medicine, York HIV Research Group, York YO31 7WA, UK
    Sex Transm Dis 36:515-21. 2009
  6. ncbi Microbicides and HIV prevention: lessons from the past, looking to the future
    Georgina C Morris
    Centre for Immunology and Infection, Hull York Medical School, University of York, York, UK
    Curr Opin Infect Dis 23:57-63. 2010
  7. ncbi Genital human papillomavirus genotypes in northwestern Tanzania
    Philippe Mayaud
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom
    J Clin Microbiol 41:4451-3. 2003
  8. ncbi Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    J Infect Dis 192:2099-107. 2005

Collaborators

Detail Information

Publications8

  1. ncbi Therapy for genital human papillomavirus-related disease
    Charles J N Lacey
    Hull York Medical School, University of York, Heslington, York YO10 5DD, UK
    J Clin Virol 32:S82-90. 2005
    ..Specific treatment considerations apply to genital warts in pregnancy and laryngeal papillomatosis and these are also discussed...
  2. ncbi Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study
    Charles J N Lacey
    Hull York Medical School, University of York, Heslington, York, UK
    AIDS 20:1027-30. 2006
    ..To directly measure the cervico-vaginal lavage (CVL) and plasma PRO 2000 concentrations achieved by vaginal dosing...
  3. ncbi Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease
    Charles J N Lacey
    Hull York Medical School, University of York, Heslington, York, UK
    Vaccine 24:S3/35-41. 2006
    ..Cost-effectiveness analyses are needed to assess the benefits of the HPV-6/11 virus-like particle (VLP) components of the quadrivalent vaccine in population-based vaccination programmes...
  4. ncbi Unacceptable side-effects associated with a hyperosmolar vaginal microbicide in a phase 1 trial
    C J Lacey
    Centre for Immunology and Infection, Hull York Medical School, University of York, York, UK
    Int J STD AIDS 21:714-7. 2010
    ..The osmolality and rheology of candidate microbicides and other genital mucosal products should therefore be analysed and considered at an early stage of product development...
  5. ncbi Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom
    Sarah C Woodhall
    Hull York Medical School, University of York, Department of GU Medicine, York HIV Research Group, York YO31 7WA, UK
    Sex Transm Dis 36:515-21. 2009
    ..We investigated the cost of treatment and period of time for which QoL is affected to obtain estimates of quality-adjusted life year (QALY) loss associated with an episode of genital warts...
  6. ncbi Microbicides and HIV prevention: lessons from the past, looking to the future
    Georgina C Morris
    Centre for Immunology and Infection, Hull York Medical School, University of York, York, UK
    Curr Opin Infect Dis 23:57-63. 2010
    ....
  7. ncbi Genital human papillomavirus genotypes in northwestern Tanzania
    Philippe Mayaud
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom
    J Clin Microbiol 41:4451-3. 2003
    ..A multivalent vaccine for HPV-16, -18, -31, -33, and -35 would be necessary to prevent 50% of the neoplasia in this population...
  8. ncbi Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    J Infect Dis 192:2099-107. 2005
    ..A therapeutic vaccine composed of HPV-6 L2E7 fusion protein and AS02A adjuvant was evaluated in conjunction with conventional therapies in subjects with anogenital warts...